Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
Sarepta Therapeutics, Inc. (SRPT) Q3 2022 Earnings Call Transcript
09:52pm, Wednesday, 02'nd Nov 2022
Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q3 2022 Results Conference Call November 2, 2022 4:30 PM ET Company Participants Mary Jenkins - Senior Manager, IR Doug Ingram - President and CEO Ian Estepan
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
10:20am, Tuesday, 01'st Nov 2022 Zacks Investment Research
Sector ETF report for FXH
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10:00pm, Monday, 31'st Oct 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on October 31, 2022 th
3 Unstoppable Stocks That Could Double in 5 Years
10:00am, Saturday, 29'th Oct 2022 The Motley Fool
The opportunities for these innovators are tremendous.
3 Unstoppable Stocks That Could Double in 5 Years
06:00am, Saturday, 29'th Oct 2022
The opportunities for these innovators are tremendous.
Fulcrum Therapeutics, Inc. (FULC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
02:02pm, Thursday, 27'th Oct 2022 Zacks Investment Research
Fulcrum Therapeutics, Inc. (FULC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Sarepta Therapeutics (SRPT) Q3 Earnings Expected to Decline
02:01pm, Wednesday, 26'th Oct 2022 Zacks Investment Research
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
I Called This October Rally In August, Keep Your Seat Belts On
03:17am, Monday, 24'th Oct 2022 Seeking Alpha
After a barely discernible bottoming process, the rally has become obvious. Read more to see how I intend to take advantage of this rally.
2 Under-the-Radar Biotech Stocks to Buy in 2022
01:53pm, Wednesday, 19'th Oct 2022 The Motley Fool
These two drugmakers are growing in prominence.
2 Under-the-Radar Biotech Stocks to Buy in 2022
09:53am, Wednesday, 19'th Oct 2022
These two drugmakers are growing in prominence.
Apple To $177? Plus This Analyst Slashes PT On Opendoor Technologies By About 71%
11:24am, Monday, 17'th Oct 2022 Benzinga
Morgan Stanley cut Apple Inc. (NASDAQ: AAPL) price target from $180 to $177. Apple shares rose 1.1% to $139.95 in pre-market trading.
Piper Sandler cut Patterson Companies, Inc. (NASDAQ: PDCO) pri
7 Analysts Have This to Say About Sarepta Therapeutics
01:05pm, Thursday, 13'th Oct 2022 Benzinga
Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:SRPT) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
2
4
Is Pfizer Stock Still Worth Buying After The Pandemic?
08:43am, Wednesday, 12'th Oct 2022 Investing.com
Big-Cap S&P Stocks Will Soon Provide Tech-Like Returns, I Explain
04:10am, Monday, 10'th Oct 2022 Seeking Alpha
Learn more about an opportunity to acquire well-known big-cap names in the S&P 500 that, at this point, could provide "tech-like" returns.
Sarepta Therapeutics Presents New Data from its Gene Therapy and RNA Platforms at World Muscle Society 2022
12:30pm, Friday, 07'th Oct 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will share new data from across its genetic
